Intervention not reported
Breast cancer stage at the time of presentation: defined as the proportion of women with breast cancer diagnosed at early stage (stage 0, I, II) Time of outcome assessment: 3 years to 20 years Method of measurement: CBE · health workers
The intervention may leads to higher breast cancer stage at the time of presentation: defined as the… (low certainty).
1 finding from 1 review
Shoulder range of motion for abduction ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for forward flexion ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for forward flexion ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for external rotation ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Shoulder range of motion for internal rotation ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Lymphoedema ‐ medium term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
It is very uncertain whether early shoulder mobilising exercises changes lymphoedema ‐ medium term compared with delayed shoulder mobilising exercises (very low certainty).
1 finding from 1 review
Shoulder range of motion for abduction ‐ short term · patients at risk for secondary upper limb lymphoedema after breast cancer treatment
1 finding from 1 review
Intervention not reported
Early mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower early mortality Rates of patients (low certainty).
1 finding from 1 review
Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
Participants requiring chemotherapy delays · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Participants requiring dose reduction · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · early triple‐negative breast cancer
1 finding from 1 review
Quality of life · early triple‐negative breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Disease-free survival · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review